Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 12TCr 8.34Cr 7.3Cr 6.73Cr 6.24Cr 12Cr 795.32Cr 12Cr 81Cr 31Cr 390.39Cr 31Cr 31Cr 1.35TCr P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 36TCr 24Cr 21Cr 19Cr 18Cr 34Cr 2.27TCr 34Cr 230.08Cr 90Cr 1.12TCr 89Cr 88Cr 3.87TCr EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
11/05 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
07/05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
07/03 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
06/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/25/09 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
06/24/06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
13/24/13 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
07/24/07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
11/24/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
10/23/10 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
1 day-2.84%
1 week-1.91%
Current month-1.91%
1 month-5.52%
3 months-8.88%
6 months-20.82%
Current year-22.03%
1 week 1,520
Extreme 1520
1,615
1 month 1,520
Extreme 1520
1,670
Current year 1,420
Extreme 1420
2,130
1 year 945
Extreme 945
2,300
3 years 480.5
Extreme 480.5
2,300
5 years 208.5
Extreme 208.5
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 29/04/2025
Corporate Officer/Principal - 29/04/2025
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-2.84%-1.91%+12.41%+205.56% 8.34Cr
+3.02%+3.40%+60.47%+174.35% 1,07000Cr
+3.36%+5.57%+72.67%+68.36% 62TCr
+1.06%+2.38%+37.30%+90.13% 45TCr
+2.14%-2.07%+27.62%+22.57% 33TCr
+2.16%+1.99%+40.73%+42.24% 29TCr
+1.44%+0.13%+29.84%+49.26% 28TCr
+1.98%+4.08%-25.78%-39.02% 22TCr
+0.79%+2.17%+26.29%+69.20% 20TCr
+3.75%+6.62%+20.51%+81.01% 16TCr
Average +1.73%+0.69%+30.21%+76.36% 36.24TCr
Weighted average by Cap. +2.45%+0.70%+43.93%+88.79%

Financials

2024 2025
Net sales 9.18TCr 6.15Cr 5.39Cr 4.96Cr 4.61Cr 8.75Cr 587.06Cr 8.87Cr 59Cr 23Cr 288.17Cr 23Cr 23Cr 999.11Cr 13TCr 8.5Cr 7.44Cr 6.85Cr 6.36Cr 12Cr 810.47Cr 12Cr 82Cr 32Cr 397.83Cr 32Cr 31Cr 1.38TCr
Net income 2.38TCr 1.6Cr 1.4Cr 1.29Cr 1.2Cr 2.27Cr 152.5Cr 2.3Cr 15Cr 6.01Cr 75Cr 6Cr 5.87Cr 259.54Cr 308.78Cr 20.7L 18.13L 16.7L 15.5L 29.44L 20Cr 29.84L 2Cr 77.8L 9.69Cr 77.75L 76.04L 34Cr
Net Debt 13TCr 8.96Cr 7.85Cr 7.23Cr 6.71Cr 13Cr 854.73Cr 13Cr 87Cr 34Cr 419.55Cr 34Cr 33Cr 1.45TCr 23TCr 15Cr 14Cr 12Cr 12Cr 22Cr 1.48TCr 22Cr 149.57Cr 58Cr 725.28Cr 58Cr 57Cr 2.51TCr
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
06/26/06 ARS 1,540.00 -2.84% 7,268
03/26/03 ARS 1,585.00 -0.31% 3,541
02/26/02 ARS 1,590.00 +1.60% 4,119
01/26/01 ARS 1,565.00 -0.32% 2,683
30/26/30 ARS 1,570.00 0.00% 21,565
  1. Stock Market
  2. Stocks
  3. RICH Stock